[Clinical studies of panipenem/betamipron in pediatrics].

Abstract

We conducted clinical studies on panipenem/betamipron (PAPM/BP), a newly developed parenteral carbapenem antibiotic, for its clinical application in the field of pediatrics. 1. A clinical study was performed on 13 children with infections, including 6 with acute bronchopneumonia, 1 each with acute pharyngitis, acute bronchitis, sepsis, staphylococcal scalded skin syndrome, urinary tract infection, subcutaneous abscess and furuncle. PAPM/BP was administered by intravenous drip infusion. Doses varied from 12 to 27 mg/kg body weight were given t.i.d. or q.i.d. Lengths of treatment ranged from 4 to 25 days. Clinical efficacies were excellent in 3 and good in 9 cases, with an efficacy rate of 92%. 2. No adverse reactions were observed. In laboratory tests, elevations of GOT, GPT and urobilinogen were observed in 3 cases. It was concluded that PAPM/BP was a promising drug for the treatment of bacterial infections in children.

• Authors: H Morita, F Hamada, M Fujieda, T Hosokawa, A Maeda, H Maeda, M Hashizume, S Kido, H Hisakawa, K Kawakubo
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 45 Issue 4 Pg. 437-42 (Apr 1992) ISSN: 0368-2781 [Print] Japan
• PMID: 1518127 (Publication Type: Clinical Trial, English Abstract, Journal Article)

Chemical References

• Thienamycins
• beta-Alanine
• panipenem-betamipron

Topics

• Adolescent
• Age Factors
• Bacterial Infections (drug therapy)
• Child
• Child, Preschool
• Drug Evaluation
• Drug Therapy, Combination (administration & dosage, adverse effects, therapeutic use)
• Female
• Humans
• Infant
• Infusions, Intravenous
• Male
• Thienamycins (administration & dosage, adverse effects, therapeutic use)
• beta-Alanine (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)